Loading
A phase 1/2 trial of Pembrolizumab in head and neck squamous cell carcinoma and colorectal cancer, run by TiumBio Co., Ltd., now recruiting.
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05784688 by TiumBio Co., Ltd., with 140 participants planned, started 2023-03-10 and due to reach its primary completion in 2026-12. Interventions recorded: TU2218 + KEYTRUDA® (Pembrolizumab). Conditions listed: Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/